Colistin-degrading proteases confer collective resistance to microbial communities during polymicrobial infections

Microbiome. 2022 Aug 19;10(1):129. doi: 10.1186/s40168-022-01315-x.

Abstract

Background: The increasing prevalence of resistance against the last-resort antibiotic colistin is a significant threat to global public health. Here, we discovered a novel colistin resistance mechanism via enzymatic inactivation of the drug and proposed its clinical importance in microbial communities during polymicrobial infections.

Results: A bacterial strain of the Gram-negative opportunistic pathogen Stenotrophomonas maltophilia capable of degrading colistin and exhibiting a high-level colistin resistance was isolated from the soil environment. A colistin-degrading protease (Cdp) was identified in this strain, and its contribution to colistin resistance was demonstrated by growth inhibition experiments using knock-out (Δcdp) and complemented (Δcdp::cdp) mutants. Coculture and coinfection experiments revealed that S. maltophilia carrying the cdp gene could inactivate colistin and protect otherwise susceptible Pseudomonas aeruginosa, which may seriously affect the clinical efficacy of the drug for the treatment of cystic fibrosis patients with polymicrobial infection.

Conclusions: Our results suggest that Cdp should be recognized as a colistin resistance determinant that confers collective resistance at the microbial community level. Our study will provide vital information for successful clinical outcomes during the treatment of complex polymicrobial infections, particularly including S. maltophilia and other colistin-susceptible Gram-negative pathogens such as P. aeruginosa. Video abstract.

Keywords: Antimicrobial resistance; Colistin; Colistin-degrading protease; Collective resistance; Polymicrobial infection; Stenotrophomonas maltophilia.

Publication types

  • Video-Audio Media

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Coinfection* / microbiology
  • Colistin / pharmacology
  • Drug Resistance, Multiple, Bacterial*
  • Gram-Negative Bacterial Infections* / drug therapy
  • Gram-Negative Bacterial Infections* / microbiology
  • Humans
  • Microbial Sensitivity Tests
  • Microbiota*
  • Peptide Hydrolases / genetics
  • Peptide Hydrolases / therapeutic use
  • Pseudomonas aeruginosa / drug effects
  • Pseudomonas aeruginosa / genetics
  • Stenotrophomonas maltophilia / enzymology

Substances

  • Anti-Bacterial Agents
  • Peptide Hydrolases
  • Colistin